Sunday 18 October 2026
Export NUWE’s income statement to Excel — free account
Nuwellis, Inc.
NUWE Healthcare Medical Devices
Nuwellis, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $8.3 million, down 5.38% from fiscal 2024. In the quarter to June 2026, revenue grew 14.1%, EPS grew 98.8% and free cash flow fell 51.6%, each against the same quarter a year earlier.
0.55
0.00
0.00%
Follow NUWE
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
0.34 | 0.15 | 0.25 | 0.06 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(0.89) | (0.40) | (0.70) | (0.17) | |
P/B ratio |
0.72 | 0.46 | 0.82 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.86 | 0.00 | |
EV/Sales |
0.45 | 0.49 | 0.46 | 0.06 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(0.39) | (0.38) | (0.36) | (0.05) | |
EV/FCF |
(0.39) | (0.37) | (0.35) | (0.05) | |
Quick Ratio |
1.20 | 0.85 | 0.98 | 1.36 | |
Current Ratio |
2.04 | 1.71 | 1.56 | 1.97 | |
Net Debt/EBITDA |
1.24 | 0.42 | 0.46 | 1.25 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
1.11 | 1.03 | 1.26 | 0.98 | |
Operating CF/Net income |
(6.71) | 1.25 | 0.69 | 0.66 | |
Capex/Depreciation |
(0.48) | (0.09) | (3.16) | (0.24) | |
Interest Coverage |
— | — | — | (0.52) | |
Research and Development Expense of Revenue |
27.20% | 36.47% | 71.91% | 47.84% | |
Selling, General and Administrative Expense of Revenue |
159.63% | 132.55% | 188.26% | 189.18% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.02 | 0.01 | |
Share Based Compensation of Revenue |
0.86% | 0.99% | 1.04% | 1.12% | |
Graham Net Nets |
1.12 | 1.42 | 0.70 | (5.92) | |
Graham Number |
0.00 | 0.00 | 0.00 | 183.94 | |
Earnings Yield |
(3,217.95%) | (5,220.16%) | (6,091.06%) | (4,347.05%) | |
Free Cash Flow Yield |
(335.69%) | (911.62%) | (532.10%) | (2,294.18%) | |
Revenue per Share |
92.76 | 123.05 | 40.52 | 10.87 | |
Operating CF per Share |
(131.67) | (153.81) | (52.48) | (17.52) | |
Capex per Share |
(4.10) | 0.61 | (2.02) | (0.05) | |
Free Cash Flow per Share |
(135.77) | (153.20) | (54.50) | (17.57) | |
Cash per Share |
129.46 | 55.08 | 35.13 | 21.64 | |
Shareholders Equity per Share |
163.51 | 133.50 | 45.01 | (11.29) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
163.51 | 133.50 | 45.01 | (11.29) | |
Free Cash Flow |
(3.24) | (3.02) | (3.23) | (3.18) | |
Working Capital |
3.68 | 2.15 | 2.10 | 3.89 | |
Capital Expenditures |
(0.10) | 0.01 | (0.12) | (0.01) | |
Net Current Asset Value |
3.14 | 1.70 | 1.54 | (3.27) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.04 | 0.00 | 0.05 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
1.22 | 1.61 | 1.55 | 1.37 | |
Average Payables |
2.25 | 1.93 | 2.08 | 2.95 | |
Average Inventory |
2.03 | 1.81 | 1.77 | 1.89 | |
Average Assets |
7.36 | 7.99 | 6.98 | 9.16 | |
Average Common Equity |
3.54 | 4.58 | 3.12 | (5.51) |
Columns are period end dates